Ben Hirschler

AMSTERDAM (Reuters) - An experimental drug from Novartis to treat heart failure proved equally effective regardless of the age of patients or whether they had other medical problems, clinical trial...

AMSTERDAM (Reuters) - Diabetes pills known as DPP-4 therapies got a mixed safety report on Monday as studies showed they did not raise the risk of heart attacks but might...

AMSTERDAM (Reuters) - A new blood clot preventer from Daiichi Sankyo proved as effective as widely used warfarin in treating a dangerous condition known as venous thromboembolism and caused less...

AMSTERDAM (Reuters) - A new blood clot preventer from Daiichi Sankyo proved as effective as widely used warfarin in treating a dangerous condition known as venous thromboembolism and caused less...

LONDON/HONG KONG (Reuters) - International drugmakers are under fire in emerging markets as governments crack down on high prices and corporate malpractice, raising a risk to the price premiums global...

LONDON/HONG KONG (Reuters) - International drugmakers are under fire in emerging markets as governments crack down on high prices and corporate malpractice, raising a risk to the price premiums global...

LONDON (Reuters) - The first test-tube baby to come from an embryo screened for genetic defects using a new, low-cost technique that could improve in-vitro fertilization success rates was born...

LONDON (Reuters) - The first test-tube baby to come from an embryo screened for genetic defects using a new, low-cost technique that could improve in-vitro fertilization success rates was born...

LONDON (Reuters) - Disposals are trumping acquisitions as GlaxoSmithKline slims down ready for a wave of its new medicines to reach the market. Britain's biggest drugmaker expects to sell operations...

LONDON (Reuters) - Disposals are trumping acquisitions as GlaxoSmithKline slims down ready for a wave of its new medicines to reach the market. Britain's biggest drugmaker expects to sell operations...